A silicone formulation of ganciclovir (GCV-pellet) was developed to enhance the cytotoxic effects of herpes simplex virus thymidine kinase suicide gene therapy. The effectiveness of this drug delivery system was assessed in a rat 9L gliosarcoma model. The GCV-pellets (1 mm in length and in diameter) used in this experiment contained a total amount of 0.15 mg of GCV. In vitro experiments demonstrated that GCV was gradually released over a period of 7 days. Five days after stereotactic tumor inoculation into the right caudate nucleus, a herpes simplex virus type 1 (HSV-1) vector expressing herpes simplex virus thymidine kinase (HSV-tk) (T1, 2 Â 10 6 pfu) was administered at the same location. The survival rate of the group treated with the GCVpellet was compared with that of the T1 group injected intraperitoneally (IP) with GCV (30 mg/kg/day for 7 days). The GCV-pellet-treated group had a significantly prolonged survival (a median of more than 80 days) compared with the GCV IP group (a median of 65 days) and with control groups (Po0.05). The control groups (untreated or receiving only the virus vector) had a survival of 35-38 days. The survival rate of the GCV-pellet group over 80 days was 75%, and all the rats that survived more than 80 days and did not show tumors upon histological examination of the brain were deemed cured. No toxic effects or immunological reactions were observed histologically around the pellet in brain sections from the rats treated with the GCV-pellet. After GCV-pellet inoculation into the tumor, drug concentrations were kept at 1-10 mg/g tissue for 3-4 days. When the same dose of GCV (0.15 mg) in aqueous solution was injected into the tumor, GCV concentrations reached a peak of 0.5 mg/g tissue after 30 min and decreased below measurable level within 12 h. After IP injections of 3 mg GCV, GCV concentrations in the tumor reached a peak of 5.7 mg/g tissue after 30 min and also decreased below measurable level within 12 h. This sustained release of a low and effective GCV dose with the silicone formulation significantly prolonged survival in combinations with HSV-tk expression if compared to IP administration of GCV. Histological examination suggests that the treatment appears to be safe.
Introduction
Despite recent advances in the treatment of malignant gliomas, the prognosis for these patients continues to be poor. [1] [2] [3] Current therapies involve the use of surgery, radiotherapy and chemotherapy but these measures are inadequate due to the infiltrative nature of gliomas, drug resistance and the significant morbidity associated with these procedures. 4, 5 Alternative approaches such as gene therapy to improve the treatment of these patients have been investigated. The most frequently used gene therapy model is suicide gene therapy, which is based on the use of herpes simplex virus thymidine kinase (HSV-tk) in the presence of ganciclovir (GCV) as a prodrug. [6] [7] [8] [9] Crucial to the success of this gene therapy model is the rate of delivery of the HSV-tk gene to tumor cells. Rainov 10 manually injected vector-producing cells with a non-migratory fibroblast phenotype during surgery. This phase III clinical trial did not show any significant improvement in survival if compared to standard therapy (surgery plus radiotherapy) One way to improve the results of gene therapy against malignant gliomas is by enhancing the bystander effects of the HSVtk/GCV system. 9 Several authors reported the combined use of HSV-tk/GCV and TNF-a -or connexin-43 to enhance the bystander effect. 11, 12 However, Cirenei et al 13 were unable to conclude definitely that the combina-tion of the connexin 43 gene can improve the effects of the HSV-tk/GCV model. A further method to enhance the bystander effects is to develop a more efficient delivery of the prodrug across the blood-brain and blood-tumor barrier. The direct placement of a silicone formulation containing GCV in the tumor was thought to bypass these barriers and to maintain a continuous effective dose of the prodrug, avoiding its systemic toxicity. GCV is supposed to be non-toxic and safe before phosphorylation in the cells by HSV-tk; however, toxicity is frequently observed in immunosuppressed patients with cytomegalovirus pneumonia. 14 The toxicity of GCV has been reported to cause bone marrow suppression. Silicone has a long history as a material used for intracerebral implants, and therefore we chose it because its safety has been carefully investigated in the human body. In addition, silicone is currently being used as a carrier material for other drug delivery systems. 15 In the present study, a silicone formulation of GCV (GCV-pellet) was developed and in situ inoculation of the pellet together with HSV-1 vector (T1) expressing HSV-tk was investigated in the treatment of the rat 9L gliosarcoma model.
Results
In vitro analysis of the silicone formulation and cytotoxicity of T1 with GCV The molecular weight of GCV is very low and, in order to provide a sustained low concentration release of GCV, a silicone formulation with GCV was developed. The formulation measured 1 mm in diameter and in length and contained 0.15 mg of GCV. Although the amount of GCV is relatively low compared to that delivered by intraperitoneal injection (30 mg/kg), the compound is released gradually. An in vitro release study demonstrated that 80% of the GCV was linearly released from the silicone formulation over a period of 3 days. A gradual release was subsequently observed for another 3 or 4 days (Figure 1 ).
The toxicity of T1 with GCV against 9L cells was assessed by the MTT assay. Cells were infected with T1 at an MOI of 3 and incubated with GCV for 3 days ( Figure  2) . At an MOI of 3.0, 0.16 mg/ml and 2 mg/ml of GCV could kill 75% and 95% of the cells, respectively.
Animal experiments using the 9L gliosarcoma rat model
In the right putamen of the rat's brain, 1 Â 10 5 9L rat gliosarcoma cells were inoculated stereotactically. After 5 days, the GCV-pellet was inoculated at the same coordinates together with T1 expressing the HSV-tk gene. The control group received a single daily intraperitoneal GCV injection of 30 mg/kg for 7 days. As a control, medium was injected instead of T1. The T1-negative group was divided into medium only, medium plus GCV-pellet and medium plus GCV intraperitoneal injection. Each group had a median survival of 35, 36, and 38 days, respectively ( Figure 3) . In contrast to these results, T1 only, T1 with the GCV-pellet and T1 with intraperitoneal injection of GCV induced median survivals of 38, 80 and 65 days, respectively ( Figure 3 ). The most prolonged survival was observed in the GCV-pellet with T1, with 75% of the rats surviving 80 days. After 80 days the rats were killed and the brains submitted for pathological examination. No tumor was observed in any brain of this group.
Brains were perfused and fixed with 4% paraformaldehyde, cut into 50 mm sections with a vibratome and stained with hematoxylin-eosin (HE). Brain slices from each group at 19 days (a-d) after tumor inoculation are shown in Figure 4 . Without the HSV-1 vector, tumor growth was similar for the GCV-silicone inoculation group (a) and the GCV IP group (b). With the administration of GCV-pellet, the tumor volumes of the group treated with T1 and the GCV-pellet (c) were reduced in a manner similar to that observed in the group treated with T1 plus GCV IP (d). At the time of sacrifice, 37 days after tumor inoculation, the GCV-pellet group without HSV-1 vector had large intracerebral tumors (e). All brain specimens that received the silicone formulation were analyzed by high microscopic magni- 
In vivo distribution of GCV
To examine the usefulness of the GCV-pellet as a local sustained release drug, the distribution of GCV was investigated after administration into the brain tumor. The silicone formulation is small, 1 mm in diameter and 1 mm in length, and contains 0.15 mg of GCV. Figure 5a shows the concentration of GCV in brain samples, in the tumor, CSF and serum after administration of the GCV- All rats were inoculated with 1 Â 10 5 9L gliosarcoma cells into the right frontal lobe, and 5 days later medium or HCV vector (T1) was injected into the same site. Some animals received the GCV-silicone formulation and others received intraperitoneal GCV injections for 7 days. (a) Intracerebral inoculation of medium and GCV-silicone formulation; (b) T1 intracerebral inoculation; (c) intracerebral inoculation of T1 and GCV-silicone formulation; (d) T1 intracerebral inoculation and intraperitoneal GCV injections for 7 days; (e) intracerebral inoculation of medium and GCVsilicone formulation. The animals were killed on the 37th day after tumor cell inoculation. Sustained release of ganciclovir with a silicone formulation F Miura et al pellet. After administration of the GCV-pellet into a rat brain tumor, GCV concentration in the tumor remained higher than in other sites of the brain.
On the first day, the concentration in the tumor reached about 10 mg/g (of tissue). The half-life of the intratumoral concentration was about 1 day, and 1 mg/g or more of GCV was maintained for up to 4 days. This concentration is effective for T1/GCV therapy ( Figure 2 ). In the ipsilateral and contralateral brain parenchyma, a GCV concentration of 0.5 mg/g or more was maintained. Nevertheless, GCV was not detected in serum (0.1 mg/ ml) and therefore a decrease in systemic adverse reactions could be expected. In CSF, GCV concentrations slightly lower than in the tumor were maintained, and GCV was considered to have diffused from brain/tumor tissue to the CSF.
For comparison purposes, when the same GCV dose of the GCV-pellet (0.15 mg) was administered into the brain tumor in aqueous solution, an early high intracerebral concentration was observed (Figure 5b ). However, this concentration rapidly decreased and no GCV was detected after 12 h (0.1 mg/g) in the tumor, brain parenchyma, CSF or serum.
From our previous study of GCV/HSV-tk gene therapy in a 9L gliosarcoma rat model, we knew that the intraperitoneal administration of GCV, 30 mg/kg/ day, in aqueous solution for seven consecutive days was effective in prolonging survival. A single dose of GCV, 30 mg/kg/day (=3 mg/day, a 20-fold level compared with GCV in the silicone formulation), in aqueous solution was administered intraperitoneally and GCV concentrations were measured in the brain, CSF and serum (Figure 5c ). Serum concentration reached 16 mg/ ml immediately after administration, and decreased thereafter with a half-life of about 1 h and no concentration was detected after 12 h. The concentration in the brain reached a maximum (5.7 mg/ml) 30 min after administration and decreased with a half-life of about 2 h. After 6 h it decreased to 1 mg/ml or lower and no concentration was detectable after 12 h.
Discussion
A silicone formulation containing 0.15 mg of GCV (GCVpellet) was developed to prevent the systemic side effects of GCV and to obtain a sustained release of GCV directly in the tumor for several days.
The GCV-pellet was administered once in the brain, with a continuous release of low-dose GCV for about 4 days. The resulting total amount of GCV released was 0.15 mg. If we assume that the perfusion rate is linear for 3 days, the concentration of GCV around the pellet is 2.5 mg/h (Figure 1 ). This estimate was confirmed by the determination of in vivo intracerebral GCV concentrations. The concentrations of GCV in the tumor could be maintained at 1-12 mg/g tissue for 4 days (Figure 6a) . From the in vitro kinetic analysis of GCV concentrations, 75% and 95% of 9L cells were killed by 0.16 and 2.0 mg/ ml of GCV at an MOI of 3.0 infection (Figure 2 ). This suggests that the low concentration of GCV, which could be achieved by the GCV-pellet, is enough to kill the tumor cells.
In the present study, the transfer of GCV into the brain after intraperitoneal administration of an aqueous solution was comparatively higher, and the area under the curve (AUC) of intracerebral concentration up to 6 h after administration was 13 mg h/g tissue, which was half of the AUC of serum concentration -26 mg h/ml. As the drug was given every 24 h, GCV concentration Â time changes were presumed to show repetition of the concentration pattern of a single-dose administration, thus showing a serrated pattern. Nevertheless, when intraperitoneal administration and administration of the silicone formulation were compared in terms of AUC of intracerebral concentration per mg of dose, the value was about 1/600 at the tumor site and about 1/100 in other tissues. Thus, it was shown that by using the silicone formulation as a local sustained delivery system, the drug could be effectively distributed into brain tissue.
The sustained release of a low concentration of GCV showed effectiveness in eradicating 9L gliosarcoma with HSV-tk expressed by the HSV-1 vector (T1) (Figure 3) . A total of 75% of the rats treated with T1 and the GCVpellet showed complete eradication of the tumor, while all of the four rats treated with T1 and GCV IP died at 65 days. This low-dose release of GCV was effective in the treatment of this gliosarcoma model, but might have affected the neurons around the pellet. High magnification of the brains from long surviving rats treated with the silicone formulation did not reveal any toxic or immunological reaction, as observed by HE staining (Figure 8 ). It is possible that with a longer follow-up other lesions related to the local toxicity of the GCV might have developed. However, we think that this possibility is unlikely since the GCV concentration gradually decreased. The silicone itself is inert in the brain parenchyma, as clinically proved by its use for many decades in other devices like ventricular catheters for hydrocephalus. Thus, the use of silicone implantation appears to be safe and the injected site can be monitored or targeted by computed tomography as a high-density mass or by MRI as a low-intensity signal on T1 strengthening image. This kind of sustained release of a nucleotide analog by the use of silicone formulations would be useful for the 5-FC/cytosine deaminase system as well as for the GCV/HSV-tk system. This GCV-silicone formulation is made as a coveredrod type. Since the release of GCV from this type of formulation comes mainly from the round top of the rod, not from the lateral wall, an initial burst of release can be minimized, and a linear release can be obtained. By increasing the length of the rod, the duration of release Sustained release of ganciclovir with a silicone formulation F Miura et al can be prolonged. 16 The GCV-pellet used in this experiment was cut to a 1 mm length to comply with the rat brain tumor model, and the duration of release was short and limited to 7 days. A prolonged duration of release for human trials can be achieved by using rods longer than 5 mm. The rod-shaped silicone formulation can be implanted stereotactically. In larger tumors, more than one rod might be necessary to provide an effective concentration in the whole tumor.
In conclusion, sustained release of low-dose GCV with silicone formulations appears to be safe in the brain and produces significantly prolonged survival in combinations with HSV-tk expression if compared to IP injection of GCV.
Materials and methods
Cell culture and virus production 9L rat gliosarcoma cells (kindly provided by Dr KM Culver, NIH) were maintained in DMEM supplemented with glutamine, antibiotics and 10% fetal bovine serum. Vero African green monkey kidney cells (CCL81; ATCC, Rockville, MD, USA) and 7B cells were maintained in MEM (Life Technologies, Inc., Gaithersburg, MD, USA) supplemented with glutamine, antibiotics (PSN; Life Technologies, Inc., Gaithersburg, MD, USA) and 10% fetal bovine serum (LTI, Gaithersburg, MD, USA).
12 HSV-1 stocks were prepared by infecting 7B cells, which supply the ICP4 and ICP27 proteins in trans, at a multiplicity of 0.03. Infected cells were harvested when a 100% cytopathic effect was evident and then subjected to a single burst of sonication. The virus was then separated from cell debris by centrifugation. Virus stocks were aliquoted into 2 ml cryogenic tubes (Corning Glass Works, Corning, NY, USA) and stored at À801C. Final titers averaged 2 Â 10 8 À2 Â 10 9 pfu/ml.
Construction of recombinant HSV-1 vectors
S4TK is a d120 backbone mutant and KOS strain mutant deleted for both copies of ICP4 and has the ICP4 immediate-early promoter substituted for the native tk promoter, resulting in a deletion of the HSV-1 U L 24 gene. This single mutated virus was created via homologous recombination of an ICP0-lacZ expression construct into a Sma I -Sma I deletion of U L 41 in the backbone of S4TK. Triple mutation was obtained after further deletion of ICP22 and ICP27. T1 is a triple mutated virus in which the lacZ gene was removed from the expression construct in ICP22 but which still contains the HCMV promoter and the bovine growth hormone polyadenylation sequences at this locus ( Figure 6 ).
Preparation of the GCV-silicone formulation (GCVpellet)
Silicone elastomer (Silastic TM Medical Grade ETR Elastomer Q7-4750, Dow Corning, USA) was used as the drug carrier material. Silicone elastomer part A (0.583 g) was mixed with part B (0.583 g) and GCV powder (0.30 g). The GCV content was 20% (w/w). Parts A and B differ in composition, and only after the two parts were combined did a cross-linking reaction begin. Silicone parts A, B and GCV were mixed and kneaded to obtain a uniform mixture which was placed in a syringe. Separately, a mixture of part A (50 g) and part B (50 g) was placed in another syringe. The mixtures were extruded through concentrically arranged dies (opening diameter of 1.0 mm) so that the GCV-containing silicone formed the inner part and the GCV-free silicone the outer part. The extruded ratio of the inner part and the outer part was 7:3 in volume ( Figure 7) . Then, the extruded rod was cured at room temperature for 1 week and at 601C for 1 day. After curing, the rod was cut to 1 mm in length and stored at 41C. Each sample contained 0.15 mg of GCV.
In vitro release study
The in vitro release study was performed by incubating the silicone formulation in pH 7.4 phosphate buffered saline containing 0.03% Tween 20 at 37 o C. The buffer was sampled at predetermined intervals and the quantity of GCV released GCV measured by reverse-phase highperformance liquid chromatography (HPLC).
In vitro cytotoxicity assays
In vitro cytotoxicity was examined by a standard MTT assay. 17 Cells were infected in suspension for 1 h at an MOI of 3 and then dispensed into 96-well, flat-bottomed microtiter plates (Becton Dickinson, Franklin Lakes, NJ, USA) at a concentration of 1 Â 10 4 cells in 100 ml per well. The cells were incubated with or without GCV at 371C in 5% CO 2 . On the fourth day after infection, 25 ml 3-(4,5-dimethylthiazol-2-yl)-diphenyltetrazolium bromide (MTT) solution (5 mg/ml, Sigma Chemical Co., St Louis, MO, USA) was added to each well and incubation at 371C in 5% CO 2 was continued for 30 min. Supernatants were removed and 100 ml dimethylsulfoxide was added to each well. After another 30 min incubation, absorbance was measured with an EL312e plate reader using a 570 nm filter (Biotek Instruments, Winooski, VT, USA). GCV concentrations ranged from 1 to 200 units (unit=0.01 mg/ml of GCV).
In vivo tumor implantation and viral injection
After thionembutal anesthesia (1 mg/kg), 1 Â 10 5 cells in 5 ml were injected 3 mm deep, 2 mm lateral and 2 mm anterior to the bregma in the frontal lobe of 100 g female Fisher 344 rats. After 5 days a subset of the rats were injected at the same coordinates with 2 Â 10 6 pfu of T1 or 10 ml of MEM culture buffer at a single injection point. Five rats in the virus-injected group were also given 30 mg/kg/day GCV via single daily intraperitoneal Sustained release of ganciclovir with a silicone formulation F Miura et al injections for 7 days. The other five rats of the virusinjected group were given the silicone formulation (1 mm in diameter and length) at the same coordinates of tumor injection just once. Animals were sacrificed at the onset of neurological symptoms or other signs that suggested inability to care for themselves according to guidelines set by the University of Osaka Animal Care Committee.
Intracerebral distribution of GCV measured by HPLC
To investigate the release behavior of the GCV-silicone formulation in vivo, GCV concentrations in the brain, CSF and blood were measured after a single administration of the GCV-silicone formulation (1 mm rod containing GCV 0.15 mg) into the rat brain tumor. At predetermined times, rats were killed, and blood, CSF and brain tissue, about 10 mg each from three different parts (tumor site, ipsilateral hemisphere and contralateral hemisphere), were obtained. Blood, CSF and homogenized brain specimens (10% in distilled water) were treated with 80% alcohol (ethanol/isopropyl alcohol) for deproteinization and disinfection. Then, supernatants were diluted with distilled water and applied to the cation-exchange cartridge Bond Elut s SCX (Varian Inc., USA). The cartridges were washed with distilled water and were eluted with pH 8.5 phosphate buffer containing 1 M NaCl. GCV concentrations in the eluted solutions were measured by HPLC at 254 nm. As a comparison, GCV concentrations after a single injection of GCV solution into the tumor at the same dose (0.15 mg/rat) or after a single intraperitoneal injection at a dose of 30 mg/kg (3 mg/rat) were also measured by the same method for the silicone formulation.
